Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and QTcF Study of Sembragiline in Healthy Volunteers
NCT02104648Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sembragiline in Alzheimer's disease (AD) (5 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events up to 30 days and Continuous, 12-lead, Holter electrocardiogram (ECG) recordings. Started Apr 2014; status: completed.
02
Drugs
sembragiline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02104648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104648.